JP2014513120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513120A5 JP2014513120A5 JP2014509330A JP2014509330A JP2014513120A5 JP 2014513120 A5 JP2014513120 A5 JP 2014513120A5 JP 2014509330 A JP2014509330 A JP 2014509330A JP 2014509330 A JP2014509330 A JP 2014509330A JP 2014513120 A5 JP2014513120 A5 JP 2014513120A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- amino
- thiazol
- hydroxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 5- {6-[(4-Cyclobutylpyridin-2-yl) amino] -4-methylpyridin-2-yl} -1,3-thiazol-2-yl Chemical group 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 150000003536 tetrazoles Chemical class 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 102000000551 Syk Kinase Human genes 0.000 claims 3
- 108010016672 Syk Kinase Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- CFRUPZABOQMKCQ-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(2h-triazol-4-yl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1C1=CNN=N1 CFRUPZABOQMKCQ-UHFFFAOYSA-N 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- PLPFVQVPQSDKPP-UHFFFAOYSA-N 1-bromo-5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C(Br)=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 PLPFVQVPQSDKPP-UHFFFAOYSA-N 0.000 claims 1
- QKZPKSVDOCPZRM-UHFFFAOYSA-N 1-cyano-5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=C(C(=C(C(O)=O)C=C3)C#N)CCC2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 QKZPKSVDOCPZRM-UHFFFAOYSA-N 0.000 claims 1
- VSZHJEDCDJLONV-UHFFFAOYSA-N 1-hydroxy-1-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-2,3-dihydroindene-4-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=C(C(=CC=C3)C(O)=O)CC2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 VSZHJEDCDJLONV-UHFFFAOYSA-N 0.000 claims 1
- AYTXEKRLUZLIRO-UHFFFAOYSA-N 1-hydroxy-1-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-2,3-dihydroindene-5-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 AYTXEKRLUZLIRO-UHFFFAOYSA-N 0.000 claims 1
- PNKAWGMVXIAEAY-UHFFFAOYSA-N 3-fluoro-5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC(F)=C(C(O)=O)C=C3CCC2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 PNKAWGMVXIAEAY-UHFFFAOYSA-N 0.000 claims 1
- VVDRPILAKHDJRT-UHFFFAOYSA-N 5-[5-[3,5-dibromo-4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C(Br)C(C)=C(Br)C=1NC1=CC(C(F)(F)F)=CC=N1 VVDRPILAKHDJRT-UHFFFAOYSA-N 0.000 claims 1
- NKZVAYATLJGLCB-UHFFFAOYSA-N 5-[5-[3-bromo-4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C(Br)C(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 NKZVAYATLJGLCB-UHFFFAOYSA-N 0.000 claims 1
- OEUADIBRAMZTMO-UHFFFAOYSA-N 5-[5-[4-acetamido-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(NC(=O)C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 OEUADIBRAMZTMO-UHFFFAOYSA-N 0.000 claims 1
- NFMSEOQFJLOMGS-UHFFFAOYSA-N 5-[5-[4-amino-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(N)=CC=1NC1=CC(C(F)(F)F)=CC=N1 NFMSEOQFJLOMGS-UHFFFAOYSA-N 0.000 claims 1
- RBRMYXQMGIWMSR-UHFFFAOYSA-N 5-[5-[5-bromo-4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound BrC=1C(C)=CC(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=NC=1NC1=CC(C(F)(F)F)=CC=N1 RBRMYXQMGIWMSR-UHFFFAOYSA-N 0.000 claims 1
- VWQKKAHJWNLXDK-UHFFFAOYSA-N 5-[5-[6-[(4-cyclobutyloxypyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1OC1CCC1 VWQKKAHJWNLXDK-UHFFFAOYSA-N 0.000 claims 1
- CADRNPXCAIYOFZ-UHFFFAOYSA-N 5-[5-[6-[(4-cyclohexyloxypyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1OC1CCCCC1 CADRNPXCAIYOFZ-UHFFFAOYSA-N 0.000 claims 1
- HCBQWBAQKUCWRP-UHFFFAOYSA-N 5-[5-[6-[(4-cyclohexylpyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1C1CCCCC1 HCBQWBAQKUCWRP-UHFFFAOYSA-N 0.000 claims 1
- KSASAGNLUPHYJX-UHFFFAOYSA-N 5-[5-[6-[(4-cyclopentyloxypyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1OC1CCCC1 KSASAGNLUPHYJX-UHFFFAOYSA-N 0.000 claims 1
- PXCUNDGCYQWEEF-UHFFFAOYSA-N 5-[5-[6-[(4-ethoxypyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound CCOC1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 PXCUNDGCYQWEEF-UHFFFAOYSA-N 0.000 claims 1
- PPOBWQXDXKYCNC-UHFFFAOYSA-N 5-[5-[6-[(4-ethylpyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound CCC1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 PPOBWQXDXKYCNC-UHFFFAOYSA-N 0.000 claims 1
- WMPRXXJICGIFFH-UHFFFAOYSA-N 5-[5-[6-[(4-tert-butylpyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(C)(C)C)=CC=N1 WMPRXXJICGIFFH-UHFFFAOYSA-N 0.000 claims 1
- IPCWPMKGLFZOGM-UHFFFAOYSA-N 5-[5-[6-[[4-(difluoromethyl)pyridin-2-yl]amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)F)=CC=N1 IPCWPMKGLFZOGM-UHFFFAOYSA-N 0.000 claims 1
- BMVADLQFFGSIDJ-UHFFFAOYSA-N 5-[5-[6-[[4-[4-(2-aminoethyl)piperazin-1-yl]pyridin-2-yl]amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1N1CCN(CCN)CC1 BMVADLQFFGSIDJ-UHFFFAOYSA-N 0.000 claims 1
- QFYBIVGGJCSWBY-UHFFFAOYSA-N 5-[5-[6-[[5-chloro-4-(trifluoromethyl)pyridin-2-yl]amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-5-hydroxy-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=C(Cl)C=N1 QFYBIVGGJCSWBY-UHFFFAOYSA-N 0.000 claims 1
- BZDPNAIFKATDSS-UHFFFAOYSA-N 5-acetamido-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound C1CCC2=CC(C(O)=O)=CC=C2C1(NC(=O)C)C(S1)=NC=C1C(N=1)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 BZDPNAIFKATDSS-UHFFFAOYSA-N 0.000 claims 1
- REBVQEZFKMRYTN-UHFFFAOYSA-N 5-amino-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(N)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 REBVQEZFKMRYTN-UHFFFAOYSA-N 0.000 claims 1
- FKOBAHHZUSXBIA-UHFFFAOYSA-N 5-hydroxy-1-methoxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C(OC)=C2CCCC1(O)C(S1)=NC=C1C(N=1)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 FKOBAHHZUSXBIA-UHFFFAOYSA-N 0.000 claims 1
- NOGBEJAUAKIDHX-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[(4-methylpyridin-2-yl)amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound CC1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 NOGBEJAUAKIDHX-UHFFFAOYSA-N 0.000 claims 1
- PANGETTYTUWTFZ-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[(4-piperazin-1-ylpyridin-2-yl)amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1N1CCNCC1 PANGETTYTUWTFZ-UHFFFAOYSA-N 0.000 claims 1
- KKTVBURDGTYPDU-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[(4-propan-2-ylpyridin-2-yl)amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound CC(C)C1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 KKTVBURDGTYPDU-UHFFFAOYSA-N 0.000 claims 1
- QBCYRLIFPWZAFG-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[(4-propylpyridin-2-yl)amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound CCCC1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 QBCYRLIFPWZAFG-UHFFFAOYSA-N 0.000 claims 1
- LXIZGPMVTRFUJA-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[(4-pyrazol-1-ylpyridin-2-yl)amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1N1C=CC=N1 LXIZGPMVTRFUJA-UHFFFAOYSA-N 0.000 claims 1
- IQMBHECVSOAQBU-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[(4-thiophen-3-ylpyridin-2-yl)amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1C=1C=CSC=1 IQMBHECVSOAQBU-UHFFFAOYSA-N 0.000 claims 1
- MZAZAGFIWASBSN-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(3-methylpyrazol-1-yl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N1=C(C)C=CN1C1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 MZAZAGFIWASBSN-UHFFFAOYSA-N 0.000 claims 1
- KTNJISCIFYFARB-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(4-methylpyrazol-1-yl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound C1=C(C)C=NN1C1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 KTNJISCIFYFARB-UHFFFAOYSA-N 0.000 claims 1
- MBQJUGGJAMEUOI-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound O1C(C)=NN=C1C1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 MBQJUGGJAMEUOI-UHFFFAOYSA-N 0.000 claims 1
- CGPASJOJARANMP-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(oxolan-3-yloxy)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC(N=CC=1)=CC=1OC1CCOC1 CGPASJOJARANMP-UHFFFAOYSA-N 0.000 claims 1
- OCQAZEACLVLCPN-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-1-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=CC(=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 OCQAZEACLVLCPN-UHFFFAOYSA-N 0.000 claims 1
- OKUYRLXBCYKBOD-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carbonitrile Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C#N)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 OKUYRLXBCYKBOD-UHFFFAOYSA-N 0.000 claims 1
- ARFNQZFUVYOZQV-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(N)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 ARFNQZFUVYOZQV-UHFFFAOYSA-N 0.000 claims 1
- CMHITQFLTSXUCO-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 CMHITQFLTSXUCO-UHFFFAOYSA-N 0.000 claims 1
- RKOFKUJSIQNSMM-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-n-(2h-tetrazol-5-yl)-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(=O)NC=2NN=NN=2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 RKOFKUJSIQNSMM-UHFFFAOYSA-N 0.000 claims 1
- AMNZXNBWQGXTKX-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-n-(trifluoromethylsulfonyl)-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(=O)NS(=O)(=O)C(F)(F)F)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 AMNZXNBWQGXTKX-UHFFFAOYSA-N 0.000 claims 1
- FQIHMDJKBUZCET-UHFFFAOYSA-N 5-hydroxy-5-[5-[4-methyl-6-[[4-[(2-methylpropan-2-yl)oxy]pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=CC(C)=CC=1NC1=CC(OC(C)(C)C)=CC=N1 FQIHMDJKBUZCET-UHFFFAOYSA-N 0.000 claims 1
- PLNKGQHICRZXGJ-UHFFFAOYSA-N 5-hydroxy-5-[5-[6-[(4-methoxypyridin-2-yl)amino]-4-methylpyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxylic acid Chemical compound COC1=CC=NC(NC=2N=C(C=C(C)C=2)C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(O)=O)=C1 PLNKGQHICRZXGJ-UHFFFAOYSA-N 0.000 claims 1
- GDGOCEQHFUUBSU-UHFFFAOYSA-N 5-hydroxy-n-(4-methylphenyl)sulfonyl-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C2C(C=3SC(=CN=3)C=3N=C(NC=4N=CC=C(C=4)C(F)(F)F)C=C(C)C=3)(O)CCCC2=C1 GDGOCEQHFUUBSU-UHFFFAOYSA-N 0.000 claims 1
- MLBVUHDKFGVEEM-UHFFFAOYSA-N 5-hydroxy-n-methoxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound C=1C(C(=O)NOC)=CC=C2C=1CCCC2(O)C(S1)=NC=C1C(N=1)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 MLBVUHDKFGVEEM-UHFFFAOYSA-N 0.000 claims 1
- HAABRXWJXIFASG-UHFFFAOYSA-N 5-hydroxy-n-methylsulfonyl-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(=O)NS(C)(=O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 HAABRXWJXIFASG-UHFFFAOYSA-N 0.000 claims 1
- SDNPEMVDTHPYTM-UHFFFAOYSA-N 6-bromo-1-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-3,4-dihydro-2h-naphthalen-1-ol Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(Br)C=C3CCC2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 SDNPEMVDTHPYTM-UHFFFAOYSA-N 0.000 claims 1
- JWIKEEYVOMFXFM-UHFFFAOYSA-N 7-fluoro-6-(hydroxymethyl)-1-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-3,4-dihydro-2h-naphthalen-1-ol Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC(F)=C(CO)C=C3CCC2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 JWIKEEYVOMFXFM-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- KRANMPGLKHWRMC-UHFFFAOYSA-N [5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalen-2-yl]boronic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)B(O)O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 KRANMPGLKHWRMC-UHFFFAOYSA-N 0.000 claims 1
- PZKZIBJVXYPHOW-UHFFFAOYSA-N [5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalen-2-yl]phosphonic acid Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)P(O)(O)=O)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 PZKZIBJVXYPHOW-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- ZPUOIHGTFVTKPO-UHFFFAOYSA-N methyl 5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-1-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1CCCC2(O)C(S1)=NC=C1C(N=1)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 ZPUOIHGTFVTKPO-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- UBEWDBOMJPZACU-UHFFFAOYSA-N n-cyano-5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(=O)NC#N)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 UBEWDBOMJPZACU-UHFFFAOYSA-N 0.000 claims 1
- ALRGXDCFURSIAF-UHFFFAOYSA-N n-cyclopropylsulfonyl-5-hydroxy-5-[5-[4-methyl-6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyridin-2-yl]-1,3-thiazol-2-yl]-7,8-dihydro-6h-naphthalene-2-carboxamide Chemical compound N=1C(C=2SC(=NC=2)C2(O)C3=CC=C(C=C3CCC2)C(=O)NS(=O)(=O)C2CC2)=CC(C)=CC=1NC1=CC(C(F)(F)F)=CC=N1 ALRGXDCFURSIAF-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482508P | 2011-05-04 | 2011-05-04 | |
| US61/482,508 | 2011-05-04 | ||
| PCT/US2012/035725 WO2012151137A1 (en) | 2011-05-04 | 2012-04-30 | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513120A JP2014513120A (ja) | 2014-05-29 |
| JP2014513120A5 true JP2014513120A5 (enExample) | 2015-07-16 |
| JP5934782B2 JP5934782B2 (ja) | 2016-06-15 |
Family
ID=47108006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509330A Expired - Fee Related JP5934782B2 (ja) | 2011-05-04 | 2012-04-30 | アミノ−ピリジン含有脾臓チロシンキナーゼ（Ｓｙｋ）阻害薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8796310B2 (enExample) |
| EP (1) | EP2704571B1 (enExample) |
| JP (1) | JP5934782B2 (enExample) |
| KR (1) | KR20140025500A (enExample) |
| CN (1) | CN103619170B (enExample) |
| AR (1) | AR086236A1 (enExample) |
| AU (1) | AU2012250958B8 (enExample) |
| BR (1) | BR112013028430A2 (enExample) |
| CA (1) | CA2834043A1 (enExample) |
| MX (1) | MX2013012776A (enExample) |
| RU (1) | RU2612217C2 (enExample) |
| TW (1) | TW201247663A (enExample) |
| WO (1) | WO2012151137A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| WO2012057262A1 (ja) * | 2010-10-28 | 2012-05-03 | 日本新薬株式会社 | ピリジン誘導体及び医薬 |
| WO2012151137A1 (en) * | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| CA2834062A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
| JP6267193B2 (ja) * | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| EP2863913B1 (en) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| US9376418B2 (en) | 2012-06-22 | 2016-06-28 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors |
| EP2884982B1 (en) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US20150284381A1 (en) * | 2012-11-07 | 2015-10-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
| EP2934525B1 (en) * | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| EP2988744A4 (en) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR |
| WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
| WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| SG11202103457PA (en) * | 2018-12-27 | 2021-05-28 | Nexys Therapeutics Inc | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
| EP3699167A1 (en) * | 2019-02-22 | 2020-08-26 | Sanofi | Process for preparing methyl 1-benzosuberone-7-carboxylate |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4185279A4 (en) | 2020-07-24 | 2024-05-01 | Secura Bio, Inc. | TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS |
| CN112370455A (zh) * | 2020-10-19 | 2021-02-19 | 济南大学 | 一种磺酰胺衍生物作为α-葡萄糖苷酶抑制剂及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| EP0769958B1 (en) | 1994-07-11 | 2003-04-16 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
| WO1996040781A1 (en) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION |
| JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| TWI238824B (en) * | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| CN1845915A (zh) | 2003-09-02 | 2006-10-11 | 默克公司 | 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物 |
| BRPI0416128B8 (pt) | 2003-11-03 | 2021-06-22 | Glaxo Group Ltd | dispositivo de dispensação de fluido |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| CN101166734A (zh) * | 2005-02-28 | 2008-04-23 | 日本烟草产业株式会社 | 具有Syk抑制活性的新型的氨基吡啶化合物 |
| RU2363699C2 (ru) * | 2005-02-28 | 2009-08-10 | Джапан Тобакко Инк. | Новое производное аминопиридина с ингибиторной активностью в отношении syk. |
| BRPI0607062A2 (pt) * | 2005-02-28 | 2009-08-04 | Japan Tobacco Inc | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos |
| WO2006129100A1 (en) * | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
| WO2008106202A1 (en) | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
| AU2010331927B2 (en) * | 2009-12-17 | 2013-10-10 | Merck Canada Inc. | Aminopyrimidines as Syk inhibitors |
| EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| CN102812022B (zh) | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| WO2012151137A1 (en) | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
| CA2834062A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
-
2012
- 2012-04-30 WO PCT/US2012/035725 patent/WO2012151137A1/en not_active Ceased
- 2012-04-30 MX MX2013012776A patent/MX2013012776A/es unknown
- 2012-04-30 KR KR1020137031760A patent/KR20140025500A/ko not_active Abandoned
- 2012-04-30 CA CA2834043A patent/CA2834043A1/en not_active Abandoned
- 2012-04-30 JP JP2014509330A patent/JP5934782B2/ja not_active Expired - Fee Related
- 2012-04-30 EP EP12780029.0A patent/EP2704571B1/en active Active
- 2012-04-30 BR BR112013028430A patent/BR112013028430A2/pt not_active Application Discontinuation
- 2012-04-30 US US13/704,484 patent/US8796310B2/en active Active
- 2012-04-30 RU RU2013153540A patent/RU2612217C2/ru not_active IP Right Cessation
- 2012-04-30 CN CN201280032005.1A patent/CN103619170B/zh not_active Expired - Fee Related
- 2012-04-30 AU AU2012250958A patent/AU2012250958B8/en not_active Ceased
- 2012-05-02 AR ARP120101538A patent/AR086236A1/es unknown
- 2012-05-04 TW TW101116052A patent/TW201247663A/zh unknown
-
2014
- 2014-07-10 US US14/328,329 patent/US20140323440A1/en not_active Abandoned